RBC Capital Downgrades Design Therapeutics Inc (DSGN) to Sector Perform 'pending further derisking'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
SVB MoffettNathanson Downgrades Design Therapeutics Inc (DSGN) to Market Perform
August 15, 2023 6:02 AM EDTSVB MoffettNathanson analyst Joseph Schwartz downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Market Perform with a price target of $6.00 (from $22.00).
For an analyst ratings summary and ratings history on Design Therapeutics Inc... More
Design Therapeutics (DSGN) Report Initial Data from Phase 1 Study of DT-216
August 14, 2023 4:01 PM EDTDesign Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the companys Phase 1 multiple-ascending dose (MAD) clinical trial of DT-216 in patients with Friedrich ataxia (FA). As of a data cutoff date of August 7, 2023, results showed that DT-216 was generally well-tolerated and achieved a statistically significant and dose-related increase in frataxin (FXN) mRNA levels in skeletal muscle biopsies.
FA is a multisystem degenerative disease caused by a GAA nucleotide repeat expansion in the FXN gene that impairs transcription and reduces FXN... More
